Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) financial results for the quarter ended March 31, 2014. Rexahn’s cash and investments totaled $40.3 million as of March 31, 2014, compared to $19.0 million as of December 31, 2013. Rexahn expects that its cash and cash equivalents balance as of March 31, 2014 will be sufficient to fund the Company’s operations into the first half of 2016.Rexahn Pharmaceuticals, Inc. (NYSEMKT: RNN) weekly performance is 28.75%. On last trading day company shares ended up $1.03. Analysts mean target price for the company is $2.83. Rexahn Pharmaceuticals, Inc. (NYSEMKT: RNN) distance from 50-day simple moving average (SMA50) is -6.04%.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that clinical data on Iclusig® (ponatinib) and AP26113, its investigational oral inhibitor of anaplastic lymphoma kinase (ALK), will be presented at the Annual Meeting of the American Society of Clinical Oncology being held in Chicago, May 30 to June 3, 2014. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares fell -2.26% in last trading session and ended the day on $6.50. ARIA Gross Margin is 78.90% and its return on assets is -65.80%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) quarterly performance is -24.94%.
MannKind Corporation (NASDAQ:MNKD) has excelled in developing a range of new products. The products are designed to provide relief from critical ailments and are gaining momentum in the market. MannKind has announced its quarterly results for analyzing its investments and growth to shape its strategy for coming quarters. MannKind Corporation (NASDAQ:MNKD) shares moved down -1.14% in last trading session and was closed at $6.93, while trading in range of $6.85 – $7.14. MannKind Corporation (NASDAQ:MNKD) year to date (YTD) performance is 33.27%.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, April 22nd. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.63. The company had revenue of $5.00 billion for the quarter, compared to the consensus estimate of $3.80 billion. During the same quarter in the previous year, the company posted $0.48 earnings per share. The company’s revenue for the quarter was up 97.5% on a year-over-year basis. Gilead Sciences, Inc. (NASDAQ:GILD) ended the last trading day at $80.10. Company weekly volatility is calculated as 2.02% and price to cash ratio as 17.93. Gilead Sciences, Inc. (NASDAQ:GILD) showed a positive weekly performance of 1.74%.
Leave a Reply